NeuroBo Pharmaceuticals, Inc. (NRBO)
NASDAQ: NRBO · IEX Real-Time Price · USD
3.020
-0.100 (-3.21%)
At close: Apr 23, 2024, 4:00 PM
3.010
-0.010 (-0.33%)
After-hours: Apr 23, 2024, 4:16 PM EDT

NeuroBo Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current2023202220212020201920182017201620152014
Market Capitalization
1518532865128473--
Market Cap Growth
-284.34%-85.62%-62.38%1556.82%-54.95%-86.32%16.24%---
Enterprise Value
-7-4-291676-99764930
PE Ratio
-1.44-1.44-0.33-2.12-2.91-0.24-0.74-2.53-4.86--
PB Ratio
0.891.080.222.2211.970.42-0.8721.443.52--
P/FCF Ratio
-1.65-1.65-0.40-2.14-8.01-0.72-0.80-3.14-6.58--
P/OCF Ratio
-1.66-1.66-0.40-2.14-8.01-0.74-0.80-3.14-6.58--
EV/EBITDA Ratio
0.340.342.44-1.06-2.580.40-0.57-2.30-3.31-0.34-1.58
EV/EBIT Ratio
0.340.342.44-1.06-2.570.40-0.57-2.30-3.31-0.34-1.58
EV/FCF Ratio
0.400.402.45-1.07-7.081.19-0.61-2.83-4.40-0.52-2.15
Debt / Equity Ratio
0.010.01-0.000.010.01-0.012.55--0.52-1.39
Debt / EBITDA Ratio
-0.02-0.02-0.000.00-0.01-0.01-0.30--0.78-2.78
Debt / FCF Ratio
-0.02-0.02-0.00-0.01-0.02-0.01-0.37--1.18-3.78
Quick Ratio
3.763.762.837.602.736.6912.992.895.830.410.36
Current Ratio
3.783.782.857.692.896.7817.392.986.010.410.38
Interest Coverage
---5.37---967.73-387.22-115.84--10.85-4.82
Return on Equity (ROE)
-59.40%-59.40%-115.30%-141.00%-322.70%-482.30%-185.80%-234.80%-348.60%202.10%-
Return on Assets (ROA)
-45.40%-45.40%-86.40%-122.90%-231.60%-319.40%-67.30%-136.30%-94.90%-539.20%-
Return on Capital (ROIC)
-94.07%-94.07%-90.24%-104.30%-407.24%-162.60%117.81%-236.99%-71.25%135.59%-129.13%
Earnings Yield
-84.16%-69.53%-299.32%-47.11%-34.41%-409.43%-134.41%-39.55%-20.57%--
FCF Yield
-73.22%-60.49%-250.82%-46.66%-12.49%-139.34%-125.10%-31.84%-15.19%--
Buyback Yield / Dilution
-1476.33%-1476.33%-233.62%-42.72%-210.43%-22.88%-926.78%-78.20%-102.09%-88.58%-
Total Shareholder Return
-1476.33%-1476.33%-233.62%-42.72%-210.43%-22.88%-926.78%-78.20%-102.09%-88.58%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).